HER2 as a prognostic factor in breast cancer

Sylvie Ménard, Stefania Fortis, Fabio Castiglioni, Roberto Agresti, Andrea Balsari

Research output: Contribution to journalArticle

Abstract

HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalOncology
Volume61
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2001

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Ductal Carcinoma
Breast Neoplasms
Mitotic Index
Neoplasms
Estrogens
Hormones

Keywords

  • Atypical ductal hyperplasia
  • Ductal carcinoma in situ
  • HER2
  • Infiltrating ductal carcinoma
  • Lymphoid infiltration
  • Prognostic factor
  • Tumor phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001). HER2 as a prognostic factor in breast cancer. Oncology, 61(SUPPL. 2), 67-72. https://doi.org/10.1159/000055404

HER2 as a prognostic factor in breast cancer. / Ménard, Sylvie; Fortis, Stefania; Castiglioni, Fabio; Agresti, Roberto; Balsari, Andrea.

In: Oncology, Vol. 61, No. SUPPL. 2, 2001, p. 67-72.

Research output: Contribution to journalArticle

Ménard, S, Fortis, S, Castiglioni, F, Agresti, R & Balsari, A 2001, 'HER2 as a prognostic factor in breast cancer', Oncology, vol. 61, no. SUPPL. 2, pp. 67-72. https://doi.org/10.1159/000055404
Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 2001;61(SUPPL. 2):67-72. https://doi.org/10.1159/000055404
Ménard, Sylvie ; Fortis, Stefania ; Castiglioni, Fabio ; Agresti, Roberto ; Balsari, Andrea. / HER2 as a prognostic factor in breast cancer. In: Oncology. 2001 ; Vol. 61, No. SUPPL. 2. pp. 67-72.
@article{c37989a33be24509947dc97072e4258f,
title = "HER2 as a prognostic factor in breast cancer",
abstract = "HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.",
keywords = "Atypical ductal hyperplasia, Ductal carcinoma in situ, HER2, Infiltrating ductal carcinoma, Lymphoid infiltration, Prognostic factor, Tumor phenotype",
author = "Sylvie M{\'e}nard and Stefania Fortis and Fabio Castiglioni and Roberto Agresti and Andrea Balsari",
year = "2001",
doi = "10.1159/000055404",
language = "English",
volume = "61",
pages = "67--72",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 2",

}

TY - JOUR

T1 - HER2 as a prognostic factor in breast cancer

AU - Ménard, Sylvie

AU - Fortis, Stefania

AU - Castiglioni, Fabio

AU - Agresti, Roberto

AU - Balsari, Andrea

PY - 2001

Y1 - 2001

N2 - HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.

AB - HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal status. HER2-positive tumors also contain p53 abnormalities, tend to be hormone receptor and bcl-2 negative, have lymphoid infiltration (LI) and a high mitotic index. Patients with LI who are HER2 positive have a better prognosis than those who are HER2 negative, whereas HER2-positive patients without LI have a significantly worse prognosis than HER2-negative patients. Morphological and biological alterations appear to identify two categories of breast tumor. Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC whereas DCIS is a precursor of HER2-positive IDC. The second theory fits well with two breast cancer subsets and the characteristics of ADH and DCIS. The first type of IDC occurs in older patients, progresses slowly due to estrogen dependency but is aggressive long term. The other type progresses rapidly, is HER2 positive and is more likely to occur in young patients.

KW - Atypical ductal hyperplasia

KW - Ductal carcinoma in situ

KW - HER2

KW - Infiltrating ductal carcinoma

KW - Lymphoid infiltration

KW - Prognostic factor

KW - Tumor phenotype

UR - http://www.scopus.com/inward/record.url?scp=0034761739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034761739&partnerID=8YFLogxK

U2 - 10.1159/000055404

DO - 10.1159/000055404

M3 - Article

C2 - 11694790

AN - SCOPUS:0034761739

VL - 61

SP - 67

EP - 72

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 2

ER -